Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, has awarded $665,000 in G-Rex® Grants to three investigators at the University of Minnesota's Center for Genome Engineering.
The grants were distributed to: Dr. Branden Moriarity ($300,000) for CAR-NK cell therapy development for ovarian cancer, Dr. Beau Webber ($240,000) for TIL therapy development for solid tumors, and Dr. Joseph Skeate ($125,000) for T-cell therapy development targeting Batten Disease.
ScaleReady's G-Rex Grant Program has now exceeded $40M in no-cost product commitments. The company has also launched a new free program called LEAN Cell & Gene™ in partnership with Hanson Wade to promote efficient CGT manufacturing practices.
Bio-Techne (NASDAQ: TECH) has scheduled its fourth quarter and fiscal 2025 financial results conference call for August 6, 2025, at 8:00 a.m. CDT. The company will host both a conference call and webcast to discuss the results.
Investors can access the call through a toll-free number (1-800-274-8461) or international number (1-203-518-9814) using Conference ID: TECHQ4. A webcast will be available on the company's investor relations website. For those unable to attend live, a replay will be accessible until September 6, 2025, using Conference ID 11159590.
Bio-Techne (NASDAQ: TECH) has formed a strategic distribution partnership with Spear Bio to expand global access to SPEAR UltraDetect™ immunoassays, focusing initially on neurology research. This follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.
The partnership leverages Spear Bio's Successive Proximity Extension Amplification Reaction (SPEAR) platform, which offers sensitivity 100-1000 times higher than current immunoassay platforms. The technology targets key biomarkers for neurodegenerative diseases, including pTau 231, pTau 217, GFAP, and Nf-L, with potential applications in inflammation and oncology.
Bio-Techne (NASDAQ: TECH) has announced a strategic partnership with Spear Bio to distribute next-generation ultrasensitive immunoassays for neurodegenerative disease research. The partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.
The collaboration will focus on distributing Spear Bio's SPEAR platform technology, which offers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms. The initial offering targets key Alzheimer's disease biomarkers including pTau 217, GFAP, Nf-L, and pTau 231.
This partnership leverages Bio-Techne's global distribution network and immunoassay expertise with Spear Bio's ultrasensitive technology to advance early disease detection and therapeutic development.
Bio-Techne (NASDAQ: TECH) announced that its Simple Western™ Technology was instrumental in supporting the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics.
The Simple Western platform was chosen for its superior capabilities in detecting and quantifying Collagen VII, a critical protein for ZEVASKYN's potency testing. The technology's advantages include picogram-level sensitivity, reproducibility, and minimal sample requirements, making it essential for GMP-compliant lot release testing of both viral vector and cell therapy components.
The platform successfully overcame complex analytical challenges in standardization and assay development, particularly in evaluating Collagen VII's tertiary structure under non-denaturing conditions.
Bio-Techne (NASDAQ: TECH) has announced a strategic distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions, including the Maurice system.
The collaboration aims to support the development of monoclonal antibody and gene therapy products worldwide. With over 160 approved antibody therapies globally, the partnership addresses critical quality control needs in both mAb development and the rapidly growing gene therapy sector. The integration of USP reference standards with Bio-Techne's analytical instruments will enable therapy manufacturers to achieve reliable characterization for purity, charge, size, and identity applications throughout product development.
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in three major upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 2:40 PM CDT, the Jefferies Global Healthcare Conference on June 4 at 3:45 PM EDT, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 10:40 AM EDT. Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website.
Bio-Techne (NASDAQ: TECH) will showcase its latest innovations at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting in New Orleans from May 13-17. Key highlights include the new RNAscope™ protease-free workflow for AAV vector visualization, ProPak™ GMP cytokines in dose-optimized bags, and the next-generation Simple Western Leo™ System capable of processing 100 samples in 3 hours.
The company will host a symposium on May 14th featuring presentations from industry leaders, including speakers from Dyno Therapeutics and Tessera Therapeutics. An additional talk on protein quantitation applications will be held on May 15th with speakers from Sangamo Therapeutics and Nervosave Therapeutics.